~~<i id='AE96958153'><strike id='AE96958153'><tt id='AE96958153'><pre id='AE96958153'></pre></tt></strike></i>~~

Home» explore» fashion

fashion

author：Wikipedia 2025-09-27 23:54:48 Page View：45274

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Burning questions for the 2024 JPM Healthcare Conference
Next article： In Memoriam: Notable people who died in 2023

leisure time

ChatGPT in medicine: STAT answers readers' burning questions

MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

In the gardens at Boston Children's Hospital, families find sanctuary

BostonChildren’sHospitalislocatedintheheartofthecity’sbustlingLongwoodmedicalarea.Butwithinthisdense

ChatGPT in medicine: STAT answers readers' burning questions

MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

Dems pitch expanding Medicare power to negotiate drug prices

Reps.RichardNeal(D-Mass.),Rep.FrankPallone(D-N.J.),andRep.JohnYarmuth(D-Ky.)JoeRaedle/GettyImagesWAS